EO1001 demonstrates up to ~40-fold greater potency than osimertinib in EGFR ECD-mutant tumor models EO4426 (tezacitabine) demonstrates selective targeting of DNA replication machinery and resistance ...

New research finds a new strategy for treating a deadly cancer by combining existing drugs to indirectly weaken tumor growth, ...

CStone Pharmaceuticals ('CStone,' HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key ...

A study shows that high levels of negatively charged lipids can lock growth receptors into an overactive state, driving ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

A study designed to investigate why lung cancer incidence has increased among younger nonsmokers over the past few decades ...

NEOK Bio, Inc., an oncology therapeutics company focused on the development of novel antibody drug conjugates (ADCs) for improving outcomes for cancer patients, today announced that two poster ...

Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programsPresentations reinforce potential of degraders ...

BH-501284 demonstrated high potency (median IC50 of 0.83 nM) and prolonged residence time (>54 hours) in KRAS-mutant cell lines, offering ...

A signaling pathway best known for shaping the brain before birth also helps govern how adults learn, adapt, and persist in ...

Researchers at Pennington Biomedical Research Center provide critical insight into how the brain and body work together to ...